Cell-Free DNA
The test detects fragments of DNA released into the blood by all cells in the body. Cancer cells shed distinctive DNA patterns that Galleri®'s algorithm identifies with high sensitivity for aggressive cancers.
First Galleri® Provider in the UK
From concern to clarity:
From concern to clarity:
a new frontier in early cancer detection
Preologi is proud to be the first provider in the UK to offer the Galleri® multi-cancer early detection blood test – a revolutionary breakthrough in proactive healthcare that can help you detect cancer before symptoms appear.
The process is simple: a single test costs £1,300 and includes a comprehensive analysis of your results by a trained clinician and a follow-up appointment with a specialist clinical care consultant if required.
Availability is currently limited, so register using the form below and we'll contact you about next steps.
Working with
50+ Cancer Types Screened from a single blood sample
99.6% Specificity resulting in low false positive rates – PATHFINDER 2 clinical study
Seven-fold (7X) increase in screen detected cancers vs standard UK screening programmes – PATHFINDER 2 clinical study
Clinician-Led. Every test is ordered, supervised and results-communicated by qualified clinicians. You are never alone in interpreting your results.
UK First. Preologi is the first organisation in the United Kingdom authorised to provide the Galleri® test.
Registration form
Be among the first in the UK to access the Galleri® test
About the Galleri test
A bold new era of cancer screening
The Galleri® test is a pioneering multi-cancer early detection (MCED) test developed by GRAIL, a leading life sciences company. The Galleri® test analyses cell-free DNA (cfDNA) shed by cells – including cancer cells – into the bloodstream.
By detecting methylation patterns unique to cancer, the test can identify a signal from more than 50 cancer types – and predict where the signal has originated – with a single blood sample. Many of these cancers have no currently recommended detection or screening programme in the UK.
If a cancer signal is detected, the Galleri® test can help clinicians direct follow-up investigations quickly and efficiently.
Preologi is the first UK clinical provider of the Galleri® test, enabling patients and referring clinicians to access this revolutionary technology for the first time.
Tissue of Origin
When a cancer signal is found, the test predicts where in the body it originated – guiding targeted follow-up diagnostics.
One Blood Test
No fasting, no complex preparation. A routine blood sample is all that is required.
How it works
Detection of over 50 cancers, including many with no existing NHS screening
The Galleri® test makes early detection possible by searching for a cancer signal across over 50 types of cancer, including many with no existing NHS screening.
The vast majority of cancers are caught late – at stage 3 or 4 – when treatment is significantly less effective. The five-year survival rate for late-stage cancer is often below 20%, compared with over 90% for many cancers detected at stage 1.
The Galleri® test aims to change this. By detecting a cancer signal in the blood before symptoms emerge, it enables the option for earlier interventions with the goal of better outcomes for patients.
Galleri® has been validated in PATHFINDER and PATHFINDER 2, involving 42,540 patients. Data from the NHS-Galleri® trial – the world's largest MCED study – with over 140,000 participants has now been presented.
Identifiable cancers include
Lung
Colorectal
Pancreatic
Ovarian
Oesophageal
Breast
Cervix
Gallbladder
Head & Neck
Lymphoma
Leukaemia
Stomach
Melanoma
Anus
Myeloma
+ 35 more
Your test
Simple, clear, guided by experts
From your first enquiry to receiving your results, Preologi's clinical team guides you through every step. Here's exactly what to expect.
01
Request your test with Preologi
Register for the Galleri® test, and our team will confirm your eligibility and explain everything you need to know before proceeding. The test is available to adults aged 22 and over and is recommended particularly for those with a personal or family history of cancer, or those wishing to take a proactive approach to health screening.
Note: The Galleri® test is a screening tool and does not replace existing cancer screening programmes (such as bowel, breast, or cervical detection). Your Preologi clinician will advise on how it fits into your wider health picture.
02
A simple blood draw – nothing more
The Galleri® test requires only a standard blood sample. No fasting is required beforehand. The sample is taken by a trained phlebotomist at a Preologi clinic or an approved partner, to be processed and shipped securely to GRAIL's laboratory.
The appointment typically takes 15–20 minutes. You can return to your normal activities immediately afterwards.
03
Advanced genomic analysis by GRAIL
Your blood sample is analysed at the GRAIL laboratory using Next Generation Sequencing technology. The test examines the methylation patterns on cell-free DNA fragments circulating in your blood. There are patterns that are unique to cancer cells; when detected, they can predict where in the body the cancer is from.
Laboratory processing and analysis typically takes 10–14 days from sample receipt. You will be notified as soon as your results are ready.
04
Your results – clearly explained
There are two possible outcomes:
No Cancer Signal Detected: This is the result received by the majority of people tested. It means no cancer signal was found in your blood at the time of testing. It does not guarantee the absence of cancer – some cancers may not shed detectable DNA – and it is not a substitute for existing detection programmes. This result does not predict whether you will develop cancer in the future.
Cancer Signal Detected: If a signal is found, your clinician will explain the result clearly and answer any questions you may have. The test will predict the location of the signal. Preologi will work with you to arrange rapid follow-up diagnostics through appropriate clinical channels. A Cancer Signal Detected result is not a diagnosis of cancer – confirmatory investigation is always required.
05
Whatever your result – we are with you
Preologi's clinical team provides ongoing support regardless of your result. For patients who receive a Cancer Signal Detected result, we coordinate swiftly with specialist diagnostic teams to ensure follow-up investigations are arranged without delay. For all patients and particularly those with a more elevated risk, we recommend annual testing as cancer risk evolves with age.
Preologi works with a network of leading oncologists and diagnostic radiologists to ensure any follow-up is expert-led, thorough, and timely.
For clinical providers
Offering the Galleri® test to your patients
If you are a clinical provider interested in offering the Galleri® test to your patients, please get in touch – our partnerships team will be happy to discuss referral pathways, pricing, and integration options.
FAQs
Answers to common questions
Still wondering whether the Galleri® test is right for you? Our clinical team is here to help.
Who should consider taking the Galleri test?
The Galleri® test is recommended for use in adults with an elevated risk of cancer, such as those with a family history of cancer or those over 50 years old. This may also include individuals with a personal history of cancer, smokers or former smokers, and anyone wishing to take a proactive approach to their health. Your Preologi clinician will help assess whether the test is appropriate for you.
Am I eligible for the Galleri test if I have previously had cancer?
Yes. The Galleri® test can be an extremely helpful adjunct in managing your long-term health when you are a cancer survivor. Patients must undergo all recommended post-cancer surveillance tests and follow-ups as recommended by their oncologists. The Galleri® test adds additional beneficial screening for such individuals who, unfortunately, are at increased risk of further cancer diagnosis when compared to the normal population.
Is this the same as existing cancer screening programmes?
No. The Galleri® test is a complementary tool and not a replacement for NHS screening programmes such as bowel, breast, or cervical detection. It covers many cancers for which no routine detection currently exists, providing an additional layer of screening. We recommend continuing with all age-appropriate NHS screening alongside the Galleri® test.
What does a "No Cancer Signal Detected" result mean?
A "No Cancer Signal Detected" result means that the test did not find a cancer signal in your blood at the time of testing. This can be a reassuring result, but it cannot guarantee you are cancer-free – very early-stage cancers may not yet shed detectable DNA. This result does not predict whether you will develop cancer in the future. Specific tumour biology also means that some cancers, such as thyroid cancer, are not well detected using this technique. It should be taken in context alongside other health information, not as a definitive all-clear.
What happens if a cancer signal is detected?
Receiving a "Cancer Signal Detected" result is not a cancer diagnosis. It means the test has found a signal that may be associated with cancer. Preologi's clinical team will contact you promptly, explain the result clearly, and arrange appropriate follow-up diagnostic investigations to determine whether cancer is present. Our team will support you through this process.
How accurate is the Galleri test?
The Galleri® test has a specificity of 99.6%, meaning fewer than 1 in 200 people without cancer will receive a false positive result. Sensitivity (the ability to detect cancer when present) varies by cancer type and stage; the sensitivity for detection of 12 deadly cancers (causing 2/3 of US cancer deaths) is 73.7%. The test has been validated in large clinical studies including the PATHFINDER 2 study.
How do I access the test if I'm a clinical provider?
Preologi works with clinical providers, private hospitals, and occupational health teams who wish to offer the Galleri® test to their patients. Please contact our clinical partnerships team at enquiries@preologi.com and we will be happy to discuss referral pathways, pricing, and integration options.
In the news
New blood test for more than 50 cancers 'could transform outcomes'
↗
Galleri: The multi-cancer early detection blood test, explained
↗
Experts hail 'holy grail' blood test that accurately flags fifty types of cancer before symptoms strike
↗
'Holy grail' test can pick up cancer in patients mistakenly given all clear
↗